Tenshi Pharmaceuticals Private Limited
ACTIVE
ISIN: INE435X07035
Issuer Details
Issuer Name
TENSHI PHARMACEUTICALS PRIVA...
Type of Issuer
Non PSU
Sector
Healthcare
Coupon Rate
4%
Industry
Pharmaceuticals & Biotechnol...
Issuer nature
Other
Corporate Identity Number (CIN)
U74999KA2016PTC094652
Name of the Lead Manager
-
Registrar
Integrated Enterprises (Indi...
Name of Debenture Trustee
Vistra ITCL (India) Limited
Instrument Details
Instrument name as on NSDL
4% SECURED UNRATED UNLISTED ...
Face Value (in ₹)
1000000
Total Issue size( in ₹ Cr.)
25
Category of Instrument
PLAIN VANILLA DEBENTURES
Allotment Date
14-12-2023
Redemption Date
29-08-2027
Whether Secured or Unsecured
Secured
Put Option Date
-
Call Option Date
-
Seniority in Repayment
Senior
Security Measures
Asset Coverage
Principal + Interest
Asset Percentage
300%
Details of Asset Cover
yes
Asset Type
Details of the security
Current Assets
yes
Others, Please Specify
first ranking exclusive pledge over ordinary shares of Outlook Therapeutics Inc as specified in the Debenture Documents, by Tenshi Healthcare Pte. Limited in relation to the Series C Debentures
Others, Please Specify
first ranking exclusive security, charge, lien, pledge, hypothecation, mortgage and or encumbrance over such other assets and rights of the Company and or its affiliates as may be required by the Debenture Trustee from time to time
Movable Asset
Security over all Pledged Shares, Steriscience Singapore Shares, Outlook Shares, Hypothecated Assets and Charged Assets as described under the Debenture Documents (as defined in the Debenture Trust Deed)
Trust & Retention Account /Escrow Accounts
first ranking exclusive charge, by way of hypothecation, by the Company in favour of the Debenture Trustee over the Series C DSRA Fixed Deposit, in accordance with the terms of the Deed of Hypothecation to secure the Debt, in relation to the Series C Debentures
Book Debts / Receivables
First ranking exclusive charge by way of hypothecation over the partnership interest of Arun Kumar Pillai, Aditya Arun Kumar, Tarini Arun Kumar, Ramaprasad JS and Barclays Wealth Trustees India Private Limited Re. Karuna Family Private Trust in Karuna Business Solutions LLP. in accordance with the terms of the Debenture Trust Deed and the deed of hypothecation (on the rights and interests of the partners in a limited liability partnership
Others, Please Specify
first fixed charge over the ordinary shares and redeemable preference shares of Steriscience Pte Ltd by Sixrays Holdings Pte Ltd in accordance with the terms of the Debenture Trust Deed and certain Singapore law governed deeds of share charge and
Non-Current Investments
yes
Trust & Retention Account /Escrow Accounts
First ranking exclusive charge by way of hypothecation over the Account Assets as defined in the Debenture Trust Deed other than the SeriesA DSRA Fixed Deposit, SeriesD DSRA Fixed Deposit and the Company Fixed Deposit by each of the Company and Karuna Business Solutions LLP in accordance with the terms of the Debenture Trust Deed and the deed of hypothecation, as may be amended or amended and restated from time to time
Others, Please Specify
first ranking exclusive charge, by way of a first ranking exclusive pledge over the Pledged Shares (as defined in the Debenture Trust Deed) by, inter alia, Mr. Arun Kumar Pillai, the Company, Karuna Business Solutions LLP, Karuna Ventures Private Limited, Pronomz Ventures LLP, Agnus Capital LLP, Agnus Holdings Private Limited, Agnus Ventures LLP, Chayadeep Properties Private Limited, Chayadeep Ventures LLP and any other obligors in accordance with the terms of the Debenture Trust Deed and other
Disclaimer: Tap Bonds gathers data directly from the respective OBPP websites but does not guarantee its accuracy. We do not offer investment advice or endorse the purchase of any securities mentioned, nor do we warrant the reliability of the information collected.
Similar Bonds
TENSHI PHARMACEUTICALS PRIVATE LIMITED
ISIN: INE435X07043
Coupon Rate
4%
Face Value (in ₹)
1000000
TENSHI PHARMACEUTICALS PRIVATE LIMITED
ISIN: INE435X08025
Coupon Rate
4%
Face Value (in ₹)
100000
TENSHI PHARMACEUTICALS PRIVATE LIMITED
ISIN: INE435X08017
Coupon Rate
4%
Face Value (in ₹)
100000
TENSHI PHARMACEUTICALS PRIVATE LIMITED
ISIN: INE435X07027
Face Value (in ₹)
1000000
About Tenshi Pharmaceuticals Private Limited bond with ISIN: INE435X07035
In the competitive landscape of fixed income securities, detailed and comprehensive information is vital for both investors and market analysts. This bond, identified by the unique ISIN INE435X07035, represents a significant financial instrument. Issued by TENSHI PHARMACEUTICALS PRIVATE LIMITED, it comes with the following description: "4% SECURED UNRATED UNLISTED REDEEMABLE NON CONVERTIBLE DEBENTRUE SERIES C DATE OF MATURITY 29/08/2027". Although the bond is currently marked as active, its structure and historical context provide valuable insights into the world of debentures and non-convertible securities. The issuer, TENSHI PHARMACEUTICALS PRIVATE LIMITED, classified as Non PSU, plays an essential role in the market despite some details such as sector, industry, and issuer nature not being explicitly provided. Key identifiers like the Corporate Identification Number (CIN) U74999KA2016PTC094652 further bolster its credibility. With a coupon rate of 4, this instrument has been meticulously managed with the assistance of Integrated Enterprises (India) Ltd., Bangalore and under the oversight of Vistra ITCL (India) Limited, ensuring a strong operational framework. Examining the technical specifications, the bond’s face value is 1000000 with an issue size of 25. It was allotted on 12/14/2023 and is scheduled for redemption on 8/29/2027. Categorized under "PLAIN VANILLA DEBENTURES" and defined as Secured, the instrument is structured to meet specific investment objectives. Although options such as call or put are not applicable in this instance, the core attributes remain detailed and robust. A critical element in evaluating any fixed income instrument is its credit rating. No credit rating information is available for this bond. This insight helps potential investors understand that while the ratings spectrum is broad, a lower rating can indicate higher risk, prompting careful consideration before investing. The security measures add another layer of assurance. The asset cover is described as follows: yes – a feature that, while requiring further inquiry for complete details, underscores the issuer’s commitment to providing some level of investor protection. Furthermore, the bond is supported by several documents. There are no additional documents available for this bond. These documents serve as a reference for additional details and provide transparency to interested parties. Additionally, there are similar bonds in the market such as the bond with ISIN INE435X07043 having a coupon rate of 4% and the bond with ISIN INE435X08025 having a coupon rate of 4% and the bond with ISIN INE435X08017 having a coupon rate of 4% and the bond with ISIN INE435X07027 having a coupon rate of N/A. Such comparable instruments offer a broader perspective on market positioning and allow investors to perform benchmark analysis. This detailed description is crafted to meet rigorous content standards and to offer exhaustive insights into every facet of the bond’s structure. Investors, analysts, and researchers alike can derive substantial value from this narrative, which underscores both the instrument’s inherent characteristics and its broader market positioning. Such elaborate coverage enhances investor confidence by providing a rich, comprehensive content base. Every element from issuance details to security measures and comparative insights is meticulously presented to facilitate an informed and robust market understanding.